Dr Reddys Laboratories Aktie - RDY

Rendering Error

Professionelle Tools für Privatanleger.

Premium

Current Price

13,16

Gebot

Fragen

Volumen

0,00 Tagesbereich 0,00

12,50 52-Wochen-Bereich 16,892

Marktkapitalisierung

10,981B

Handelsende

13,16

Handelsbeginn

Letzte Trade

Letzter Handelszeitpunkt

Finanzvolumen

VWAP

Durchschnittliches Volumen (3 Mio.)

1.965.628

Ausgegebene Aktien

834.385.730

Dividendenrendite

Kurs-Gewinn-Verhältnis

0,00

Gewinn pro Aktie (EPS)

Erlöse

282,45B

Nettogewinn

55,78B

Headquartered in India, Dr. Reddy's Laboratories develops and manufactures generic pharmaceutical products sold across the world. The company specializes in low-cost, easy-to-produce small-molecule generic drugs and active pharmaceutical ingredients. Its drug portfolio in recent years has included b... Headquartered in India, Dr. Reddy's Laboratories develops and manufactures generic pharmaceutical products sold across the world. The company specializes in low-cost, easy-to-produce small-molecule generic drugs and active pharmaceutical ingredients. Its drug portfolio in recent years has included biosimilar drug launches in select emerging markets and has shifted toward injectables and more complex generic products. Geographically, the company's sales are well dispersed across North America, India, and other emerging markets. Mehr anzeigen

Sektor

Pharmaceutical Preparations

Branche

Pharmaceutical Diversified

Website

www.drreddys.com

Hauptsitz

Hyderabad, Andhra Pradesh, Ind

Gegründet

1984

Dr Reddys Laboratories Ltd is listed in the Pharmaceutical Preparations sector of the New York Börse with ticker RDY. The last closing price for Dr Reddys Laboratories was US$13,16. Over the last year, Dr Reddys Laboratories shares have traded in a share price range of US$ 12,50 to US$ 16,892.

Dr Reddys Laboratories currently has 834.385.730 shares in issue. The market capitalisation of Dr Reddys Laboratories is US$10,98 billion.

Bio-Thera and Dr. Reddy's Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, and BAT2506, a Proposed Simponi® Biosimilar, for Southeast Asia

Bio-Thera and Dr. Reddy's Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara®...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Alvotech and Dr. Reddy’s Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as “Dr...

Alvotech and Dr. Reddy’s Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

HYDERABAD, India and REYKJAVIK, Iceland, March 18, 2025 (GLOBE NEWSWIRE) -- Dr. Reddy’s Laboratories Ltd...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	-0.15	-1.12697220135	13.31	13.41	13.1	2401784	13.2285004	CS
4	0.24	1.85758513932	12.92	13.85	12.5	1930976	13.20226597	CS
12	-2.57	-16.3382072473	15.73	15.82	12.5	1965628	13.7581078	CS
26	-2.74600024	-17.2639268111	15.90600024	16.04	12.5	1409022	14.14267588	CS
52	-1.60800022	-10.8884086948	14.76800022	16.89200025	12.5	809325	14.27792157	CS
156	1.88999983	16.770184574	11.27000017	16.89200025	9.91800015	419531	13.51280895	CS
260	5.23799988	66.1196642345	7.92200012	16.89200025	7.87800012	318166	13.23310351	CS

RDY - Frequently Asked Questions (FAQ)

What is the current Dr Reddys Laboratories share price?

The current share price of Dr Reddys Laboratories is US$ 13,16

How many Dr Reddys Laboratories shares are in issue?

Dr Reddys Laboratories has 834.385.730 shares in issue

What is the market cap of Dr Reddys Laboratories?

The market capitalisation of Dr Reddys Laboratories is USD 10,98B

What is the 1 year trading range for Dr Reddys Laboratories share price?

Dr Reddys Laboratories has traded in the range of US$ 12,50 to US$ 16,892 during the past year

What is the reporting currency for Dr Reddys Laboratories?

Dr Reddys Laboratories reports financial results in INR

What is the latest annual turnover for Dr Reddys Laboratories?

The latest annual turnover of Dr Reddys Laboratories is INR 282,45B

What is the latest annual profit for Dr Reddys Laboratories?

The latest annual profit of Dr Reddys Laboratories is INR 55,78B

What is the registered address of Dr Reddys Laboratories?

The registered address for Dr Reddys Laboratories is 8-2-337, ROAD NO. 3, BANJARA HILLS, TELANGANA, HYDERABAD, ANDHRA PRADESH, 500034

What is the Dr Reddys Laboratories website address?

The website address for Dr Reddys Laboratories is www.drreddys.com

Which industry sector does Dr Reddys Laboratories operate in?

Dr Reddys Laboratories operates in the PHARMACEUTICAL DIVERSIFIED sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
SRLScully Royalty Ltd	US$ 12,79 (58,70%)	6
JQCNuveen Credit Strategies Income Fund	US$ 7,99 (49,63%)	63
AVDAmerican Vanguard Corporation	US$ 6,39 (44,90%)	2
CURVTorrid Holdings Inc	US$ 7,49 (40,00%)	2
SMHISEACOR Marine Holdings Inc	US$ 6,90 (38,00%)	6
SRGSeritage Growth Properties	US$ 2,10 (-29,29%)	304
NMAXNewsmax Inc	US$ 176,01 (-24,46%)	42,77k
ASIXAdvanSix Inc	US$ 17,01 (-24,16%)	1
AMXAmerica Movil SAB de CV	US$ 11,91 (-18,09%)	18
AMTBAmerant Bancorp Inc	US$ 17,21 (-16,66%)	7
NIONIO Inc	US$ 3,85 (-0,52%)	460,75k
IONQIonQ Inc	US$ 23,97 (3,36%)	206,79k
HIMSHims and Hers Health Inc	US$ 29,81 (-3,99%)	131,57k
QBTSD Wave Quantum Inc	US$ 7,50 (1,08%)	111,69k
STLAStellantis NV	US$ 11,15 (0,54%)	68,99k

Rendering Error

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Dr Reddys Laboratories Ltd (RDY) Börsenkurse

Dr Reddys Laboratories Ltd (RDY)

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

Über Dr Reddys Laboratories Ltd

RDY Neueste Nachrichten

Bio-Thera and Dr. Reddy's Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, and BAT2506, a Proposed Simponi® Biosimilar, for Southeast Asia

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Alvotech and Dr. Reddy’s Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

Alvotech and Dr. Reddy’s Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Bio-Thera and Dr. Reddy's Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, and BAT2506, a Proposed Simponi® Biosimilar, for Southeast Asia

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Alvotech and Dr. Reddy’s Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

Alvotech and Dr. Reddy’s Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

RDY - Frequently Asked Questions (FAQ)

Beweger

RDY Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen